AFfirm™ Bcl-2 Antibody - #BF9103

(67)   (39)  
製品: Bcl-2 Antibody
カタログ: BF9103
タンパク質の説明: Mouse monoclonal antibody to Bcl-2
アプリケーション: WB IHC IF/ICC ELISA
Cited expt.: WB, IHC, IF/ICC
反応性: Human, Mouse, Rat
分子量: 26 kd; 26kD(Calculated).
ユニプロット: P10415
RRID: AB_2837570

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $280 在庫あり
 200ul $350 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先
関連ダウンロード
MSDS
説明書
COA
プロトコル
WB Handbook
IHC Protocol
IF/ICC Protocol

製品説明

ソース:
Mouse
アプリケーション:
WB 1:1000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse,Rat
クローナリティ:
Monoclonal [AFfirm063]
特異性:
The Bcl-2 mouse monoclonal antibody can detect endogenous Bcl-2 proteins.
RRID:
AB_2837570
引用形式: Affinity Biosciences Cat# BF9103, RRID:AB_2837570.
コンジュゲート:
Unconjugated.
精製:
affinity purification.
保存:
Store at -20°C. Stable for one year from the date of shipment.1mg/ml in PBS, pH 7.4, containing 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ／展開

Apoptosis regulator Bcl 2; Apoptosis regulator Bcl-2; Apoptosis regulator Bcl2; AW986256; B cell CLL/lymphoma 2; B cell leukemia/lymphoma 2; Bcl-2; Bcl2; BCL2_HUMAN; C430015F12Rik; D630044D05Rik; D830018M01Rik; Leukemia/lymphoma, B-cell, 2; Oncogene B-cell leukemia 2; PPP1R50; Protein phosphatase 1, regulatory subunit 50;

免疫原

免疫原:

Mouse monoclonal antibody is prepared by immunizing synthetic peptide coupled to KLH.

Uniprot:

P10415(BCL2_HUMAN) >>Visit HPA database.

遺伝子(ID):
BCL2(596)
発現特異性:
P10415 BCL2_HUMAN:

Expressed in a variety of tissues.

タンパク質の説明:
BCL2 is an integral outer mitochondrial membrane protein that blocks the apoptotic death of some cells such as lymphocytes. Constitutive expression of BCL2, such as in the case of translocation of BCL2 to Ig heavy chain locus, is thought to be the cause of follicular lymphoma. BCL2 suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. It regulates cell death by controlling the mitochondrial membrane permeability.
タンパク質配列:
MAHAGRTGYDNREIVMKYIHYKLSQRGYEWDAGDVGAAPPGAAPAPGIFSSQPGHTPHPAASRDPVARTSPLQTPAAPGAAAGPALSPVPPVVHLTLRQAGDDFSRRYRRDFAEMSSQLHLTPFTARGRFATVVEELFRDGVNWGRIVAFFEFGGVMCVESVNREMSPLVDNIALWMTEYLNRHLHTWIQDNGGWDAFVELYGPSMRPLFDFSWLSLKTLLSLALVGACITLGAYLGHK

研究背景

機能:

Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release.

PTMs:

Phosphorylation/dephosphorylation on Ser-70 regulates anti-apoptotic activity. Growth factor-stimulated phosphorylation on Ser-70 by PKC is required for the anti-apoptosis activity and occurs during the G2/M phase of the cell cycle. In the absence of growth factors, BCL2 appears to be phosphorylated by other protein kinases such as ERKs and stress-activated kinases. Phosphorylated by MAPK8/JNK1 at Thr-69, Ser-70 and Ser-87, wich stimulates starvation-induced autophagy. Dephosphorylated by protein phosphatase 2A (PP2A) (By similarity).

Proteolytically cleaved by caspases during apoptosis. The cleaved protein, lacking the BH4 motif, has pro-apoptotic activity, causes the release of cytochrome c into the cytosol promoting further caspase activity.

Monoubiquitinated by PRKN, leading to increase its stability. Ubiquitinated by SCF(FBXO10), leading to its degradation by the proteasome.

細胞の位置付け:

Mitochondrion outer membrane>Single-pass membrane protein. Nucleus membrane>Single-pass membrane protein. Endoplasmic reticulum membrane>Single-pass membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
組織特異性:

Expressed in a variety of tissues.

タンパク質ファミリー:

BH1 and BH2 domains are required for the interaction with BAX and for anti-apoptotic activity.

The BH4 motif is required for anti-apoptotic activity and for interaction with RAF1 and EGLN3.

The loop between motifs BH4 and BH3 is required for the interaction with NLRP1.

Belongs to the Bcl-2 family.

研究領域

· Cellular Processes > Transport and catabolism > Autophagy - animal.   (View pathway)

· Cellular Processes > Cell growth and death > Apoptosis.   (View pathway)

· Cellular Processes > Cell growth and death > Apoptosis - multiple species.   (View pathway)

· Cellular Processes > Cell growth and death > Necroptosis.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Environmental Information Processing > Signal transduction > NF-kappa B signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Sphingolipid signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Hedgehog signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway.   (View pathway)

· Genetic Information Processing > Folding, sorting and degradation > Protein processing in endoplasmic reticulum.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Drug resistance: Antineoplastic > Platinum drug resistance.

· Human Diseases > Neurodegenerative diseases > Amyotrophic lateral sclerosis (ALS).

· Human Diseases > Infectious diseases: Parasitic > Toxoplasmosis.

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Colorectal cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Prostate cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

· Organismal Systems > Circulatory system > Adrenergic signaling in cardiomyocytes.   (View pathway)

· Organismal Systems > Immune system > NOD-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Nervous system > Neurotrophin signaling pathway.   (View pathway)

· Organismal Systems > Nervous system > Cholinergic synapse.

· Organismal Systems > Endocrine system > Estrogen signaling pathway.   (View pathway)

参考文献

1). Fully Biocompatible Tantalum-Based Antioxidant Nanoshields for Proximal Tubule Epithelial Cells-Targeted Mitochondrial Holistic Protection in Acute Kidney Injury. Advanced materials (Deerfield Beach, Fla.), 2025 (PubMed: 41122030) [IF=27.4]
2). Inhibiting Mitochondrial Damage for Efficient Treatment of Cerebral Ischemia-Reperfusion Injury Through Sequential Targeting Nanomedicine of Neuronal Mitochondria in Affected Brain Tissue. ADVANCED MATERIALS, 2024 [IF=27.4]
3). Molybdenum-bridged endo-exogenous antioxidant synergy reverses acute kidney injury via mitochondrial homeostasis reconstruction. Bioactive Materials, 2025 [IF=20.3]

Application: WB    Species: human    Sample: HK-2 cells

Fig. 5. NMDs effectively inhibited mitochondrial apoptosis. (A–B) JC-1 cytometry results (A) and corresponding statistical data (B) of HK-2 cells from different treatment groups. (C) JC-1 fluorescence staining images of HK-2 cells from different treatment groups. (D) ATP production of HK-2 cells from different treatment groups. (E–F) Annexin-V/PI flow cytometry results (E) and corresponding apoptosis ratio (F) in HK-2 cells from different treatment groups. (G–K) Western Blotting analysis (G) of apoptosis-related protein expression levels in HK-2 cells from different treatment groups and grayscale analysis of cyto-Cyt c(H), Bax (I), Bcl-2 (J), and cleaved-Caspase 3 (K). (L) Schematic illustration of NMDs inhibiting intrinsic apoptosis. (M–N) TUNEL fluorescence staining results (M) and quantification of TUNEL-positive cells (N) in mouse kidneys from different treatment groups. Data are presented as mean ± SD. One-way ANOVA followed by SNK test was used for analysis. n = 3, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001; ns, not significant (P > 0.05).
4). Passively-targeted mitochondrial tungsten-based nanodots for efficient acute kidney injury treatment. Bioactive materials, 2023 (PubMed: 36185743) [IF=18.9]

Application: WB    Species: Mouse    Sample:

Fig. 4 TWNDs reduced mitochondrial-dependent apoptosis. (A–B) TEM image of mitochondria of tubular cells in normal mouse (A) and AKI mouse (B). Scale bar: 1 μm. (C) Schematic illustration of TWNDs passing through the glomerulus to the tubular site. (D) TEM image of mitochondria of tubule cells in AKI mouse after injection of TWNDs and the magnified image. Scale bar: 1 μm. (E) Schematic illustration of ROS induced mitochondrial-dependent cell apoptosis. (F) WB analysis of BAX, BCL-2, Cyt c, KIM-1 and NGAL proteins in renal tissue homogenate from each group. (G) Quantification of the protein immunoblots of BAX, BCL-2, Cyt c, KIM-1 and NGAL. (H) MitoSOX staining (red fluorescence), DAPI (blue fluorescence) staining, and their merge images of HK-2 cells from each group. Scale bar: 10 μm. (I) Quantification of MitoSOX-positive cells in (H). (J) TUNEL staining (green fluorescence), DAPI (blue fluorescence) staining, and their merge images of kidney tissues from each group. Scale bar: 100 μm. (K) Quantification of TUNEL-positive cells in (J). (L) Immunohistochemical staining of Cyt c from each group. Scale bar: 20 μm. (M) Quantification of Cyt-c-positive rate in (L). Data represent means ± S.D. from at least three independent replicates. (*P < 0.05, **P < 0.01, ***P < 0.001 vs AKI or H2O2 group; ##P < 0.01, ###P < 0.001vs sham or control group).
5). Unlocking Neuroprotection: Simultaneous Suppression of Mitochondrial Energetic Collapse and Oxidative-Inflammatory Vortex for Ischemia-Reperfusion Brain Injury. ACS nano, 2025 (PubMed: 41124697) [IF=15.8]
6). Hierarchical Targeting Nanodrug with Holistic DNA Protection for Effective Treatment of Acute Kidney Injury. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025 (PubMed: 39703158) [IF=15.1]
7). A NRF2 Regulated and the Immunosuppressive Microenvironment Reversed Nanoplatform for Cholangiocarcinoma Photodynamic-Gas Therapy. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024 (PubMed: 38308097) [IF=15.1]
8). Melatonin receptor 1a alleviates sleep fragmentation-aggravated testicular injury in T2DM by suppression of TAB1/TAK1 complex through FGFR1. Acta pharmaceutica Sinica. B, 2025 (PubMed: 40698135) [IF=14.7]

Application: WB    Species: Mouse    Sample:

Figure 1. SF exacerbated testicular damage in mice. (A) The testis-to-body weight ratio (mg/g) and blood glucose levels (mmol/L). (B) Representative images of H&E, the number of spermatozoa in the tubule cross sections, and the representative images and quantitative analysis of AR (n = 6). (C) Relative mRNA levels of Pdcl2, Tsnaxip1, Gipr, Ddx4, and Amh in testis (n = 6). (D, E) Nuclear accumulation of NF-κB determined by IF staining with anti-NF-κB p65 antibody (red) in testis tissues (n = 6). (F) Tnfa, Il1b, and Il6 mRNA levels in the testis of T2DM and SF mice (n = 6). (G, H) Representative microphotographs and quantification of fluorescence intensity of DHE staining (red) in testis sections; IHC staining using 4-HNE and 3-NT antibody in testis tissues and related quantitative analysis (n = 6). (I) Relative mRNA levels of Hmox1, Nqo1, Sod, and Cat in testis (n = 6). (J) The protein expression levels of Cleaved Caspase-9, Cleaved Caspase-3, Cytochrome c, Bax, and Bcl-2 were assessed using Western blot analysis, with quantification of relative protein levels performed (n = 6). (K) IHC staining of testis apoptosis detected with Cytochrome c and proliferation detected with PCNA and related quantitative analysis (n = 6). Data shown in graphs represent the means ± SD; GAPDH was used as an internal control; ∗P < 0.05; NS, not significant.
9). Oral Metal-Free Melanin Nanozymes for Natural and Durable Targeted Treatment of Inflammatory Bowel Disease (IBD). Small (Weinheim an der Bergstrasse, Germany), 2023 (PubMed: 36760016) [IF=13.0]
10). Aberrant activation of p53-TRIB3 axis contributes to diabetic myocardial insulin resistance and sulforaphane protection. Journal of advanced research, 2024 (PubMed: 39069209) [IF=11.4]
もっと読みます

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.